Fever News and Research

RSS

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013

Experts develop way to reduce radiation exposure in children who require repeated brain CT scans

A team of pediatric neurosurgeons and neuroradiologists at the Johns Hopkins Children's Center has developed a way to minimize dangerous radiation exposure in children with a condition that requires repeat CT scans of the brain.

4 Oct 2013

Genetically modified bacterial treatment approach reduces or eliminates sleeping sickness

A tag team of two bacteria, one of them genetically modified, has a good chance to reduce or even eliminate the deadly disease African trypanosomiasis, or sleeping sickness, researchers at Oregon State University conclude in a recent mathematical modeling study.

4 Oct 2013

Discovery paves way for development of new medicines to combat herpes infections

Researchers at Lund University in Sweden and Carnegie Mellon University have for the first time managed to measure the internal pressure that enables the herpes virus to infect cells in the human body. The discovery paves the way for the development of new medicines to combat viral infections. The results indicate good chances to stop herpes infections in the future.

3 Oct 2013

Specialized cells play major role in inflammation that underlies Crohn's disease in small intestine

Scientists have discovered that Crohn's disease, the inflammatory bowel disorder, can originate from specialised intestinal cell type called Paneth cells. As such, they propose that small intestinal Crohn's disease might be a specific disorder of this cell type, providing a possible new target for treatments.

3 Oct 2013

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

Noven Pharmaceuticals, Inc., today announced that 11 presentations, featuring data analyses from its Phase 3 pivotal trials that supported the recent U.S. Food and Drug Administration approval of Brisdelle (paroxetine capsules, 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms associated with menopause, will be showcased at the 2013 Annual Meeting of The North American Menopause Society in Dallas on Oct. 9-10.

2 Oct 2013

FDA grants accelerated approval of Perjeta for people with HER2-positive early stage breast cancer

The U.S. Food and Drug Administration granted accelerated approval of a Perjeta- (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer.

2 Oct 2013

Circassia reports positive results from phase II clinical study of ToleroMune grass allergy treatment

Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced successful results from a large phase II clinical study of its ToleroMune® grass allergy treatment (Grass-Synthetic Peptide Immuno-Regulatory Epitope [Grass-SPIRE])

1 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

Diabetes puts you at increased risk of flu-related complications

There are certain groups of people who are at risk of serious flu complications each year, including those with diabetes.

30 Sep 2013

University of Maryland receives renewed NIH funding for vaccine research

The University of Maryland School of Medicine's Center for Vaccine Development (CVD) has successfully competed for and received a renewed contract to conduct basic research and clinical studies of vaccines, diagnostics, and therapeutics. Support for this work to combat existing and emerging infectious diseases is provided by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

27 Sep 2013

MIT engineers develop nanoparticles that deliver cancer vaccines to lungs

Many viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs, gastrointestinal tract and reproductive tract. To help fight these pathogens, scientists are working on vaccines that can establish a front line of defense at mucosal surfaces.

26 Sep 2013

First global analysis of Kawasaki disease published by PLOS ONE

After more than four decades of research, strong evidence now shows that Kawasaki disease has a distinct seasonal occurrence shared by regions across the Northern hemisphere.

24 Sep 2013

ACR journals publish guide that provides new treatments for children with systemic JIA

In the U.S., there are nearly 300,000 children with juvenile arthritis and other rheumatic illnesses according to estimates from the American College of Rheumatology (ACR). For pediatric patients with systemic juvenile idiopathic arthritis (JIA), effective treatment for this disabling disease is imperative.

24 Sep 2013

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis.

23 Sep 2013

New blood test accurately differentiates viral and bacterial infections

A blood test developed by researchers at Duke Medicine showed more than 90-percent accuracy in distinguishing between viral and bacterial infections when tested in people with respiratory illnesses.

19 Sep 2013

Inhaled corticosteroid increases risk for pneumonia reoccurrence

A University of Alberta researcher says health professionals should be cautious about prescribing inhaled corticosteroids to high-risk patients such as pneumonia survivors, citing a twofold risk for repeat infection.

19 Sep 2013

New series of lectures focus on rodents, medicines and drug developments

Rodents, medicines and drug developments are all on the agenda during a new series of public lectures being staged by the University of Greenwich's Faculty of Engineering & Science.

18 Sep 2013

Biocryst Wins Potentially $22M NIAID Contract To Develop Marburg Virus Disease Drug

...

17 Sep 2013

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

The U.S. Food and Drug Administration today approved the first generic version of Xeloda (capecitabine), an oral chemotherapy pill used to treat cancer of the colon or rectum (colorectal cancer) that has spread to other parts of the body (metastatic), and metastatic breast cancer.